PMC:7228307 / 2292-2609 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"31","span":{"begin":80,"end":84},"obj":"Gene"}],"attributes":[{"id":"A31","pred":"tao:has_database_id","subj":"31","obj":"Gene:2213"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"nipulation of IgG2, IgG4 as well as IgG1 for optimized activating or inhibitory FcγR effector functions will underpin the development of potent \"next‐gen\" antibody therapeutics.\n\nIntroduction\nThe regulatory approval of the first therapeutic monoclonal antibodies (mAbs) in the 1980s ushered in the modern era of immun"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T13","span":{"begin":155,"end":163},"obj":"Body_part"}],"attributes":[{"id":"A13","pred":"fma_id","subj":"T13","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"nipulation of IgG2, IgG4 as well as IgG1 for optimized activating or inhibitory FcγR effector functions will underpin the development of potent \"next‐gen\" antibody therapeutics.\n\nIntroduction\nThe regulatory approval of the first therapeutic monoclonal antibodies (mAbs) in the 1980s ushered in the modern era of immun"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T29","span":{"begin":55,"end":65},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T30","span":{"begin":80,"end":82},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"}],"text":"nipulation of IgG2, IgG4 as well as IgG1 for optimized activating or inhibitory FcγR effector functions will underpin the development of potent \"next‐gen\" antibody therapeutics.\n\nIntroduction\nThe regulatory approval of the first therapeutic monoclonal antibodies (mAbs) in the 1980s ushered in the modern era of immun"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T8","span":{"begin":85,"end":93},"obj":"Chemical"}],"attributes":[{"id":"A8","pred":"chebi_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_35224"}],"text":"nipulation of IgG2, IgG4 as well as IgG1 for optimized activating or inhibitory FcγR effector functions will underpin the development of potent \"next‐gen\" antibody therapeutics.\n\nIntroduction\nThe regulatory approval of the first therapeutic monoclonal antibodies (mAbs) in the 1980s ushered in the modern era of immun"}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T12","span":{"begin":94,"end":103},"obj":"http://purl.obolibrary.org/obo/BFO_0000034"}],"text":"nipulation of IgG2, IgG4 as well as IgG1 for optimized activating or inhibitory FcγR effector functions will underpin the development of potent \"next‐gen\" antibody therapeutics.\n\nIntroduction\nThe regulatory approval of the first therapeutic monoclonal antibodies (mAbs) in the 1980s ushered in the modern era of immun"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"31","span":{"begin":80,"end":84},"obj":"Gene"}],"attributes":[{"id":"A31","pred":"pubann:denotes","subj":"31","obj":"Gene:2213"}],"text":"nipulation of IgG2, IgG4 as well as IgG1 for optimized activating or inhibitory FcγR effector functions will underpin the development of potent \"next‐gen\" antibody therapeutics.\n\nIntroduction\nThe regulatory approval of the first therapeutic monoclonal antibodies (mAbs) in the 1980s ushered in the modern era of immun"}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T17","span":{"begin":179,"end":191},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"nipulation of IgG2, IgG4 as well as IgG1 for optimized activating or inhibitory FcγR effector functions will underpin the development of potent \"next‐gen\" antibody therapeutics.\n\nIntroduction\nThe regulatory approval of the first therapeutic monoclonal antibodies (mAbs) in the 1980s ushered in the modern era of immun"}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T13","span":{"begin":155,"end":163},"obj":"Body_part"}],"attributes":[{"id":"A13","pred":"fma_id","subj":"T13","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"nipulation of IgG2, IgG4 as well as IgG1 for optimized activating or inhibitory FcγR effector functions will underpin the development of potent \"next‐gen\" antibody therapeutics.\n\nIntroduction\nThe regulatory approval of the first therapeutic monoclonal antibodies (mAbs) in the 1980s ushered in the modern era of immun"}

{"project":"LitCovid-sentences","denotations":[{"id":"T17","span":{"begin":179,"end":191},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"nipulation of IgG2, IgG4 as well as IgG1 for optimized activating or inhibitory FcγR effector functions will underpin the development of potent \"next‐gen\" antibody therapeutics.\n\nIntroduction\nThe regulatory approval of the first therapeutic monoclonal antibodies (mAbs) in the 1980s ushered in the modern era of immun"}